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Abstract
Treatment of invasive adenovirus (Ad) disease in hematopoietic stem cell transplant (SCT) recipients with capsid protein
hexon-specific donor T cells is under investigation. We propose that cytotoxic T cells (CTLs) targeted to the late protein
hexon may be inefficient in vivo because the early Ad protein E3-19K downregulates HLA class I antigens in infected cells. In
this study, CD8+ T cells targeted to highly conserved HLA A2-restricted epitopes from the early regulatory protein DNA
polymerase (P-977) and late protein hexon (H-892) were compared in peripheral blood (PB) and tonsils of naturally infected
adults. In tonsils, epitope-specific pentamers detected a significantly higher frequency of P-977+CD8+ T cells compared to
H-892+CD8+ T cells; this trend was reversed in PB. Tonsil epitope-specific CD8+ T cells expressed IFN-c and IL-2 but not
perforin or TNF-a, whereas PB T cells were positive for IFN-c, TNF-a, and perforin. Tonsil epitope-specific T cells expressed
lymphoid homing marker CCR7 and exhibited lower levels of the activation marker CD25 but higher proliferative potential
than PB T cells. Finally, in parallel with the kinetics of mRNA expression, P-977-specific CTLs lysed targets as early as 8 hrs
post infection. In contrast, H-892-specific CTLs did not kill unless infected fibroblasts were pretreated with IFN-c to up
regulate HLA class I antigens, and cytotoxicity was delayed until 16–24 hours. These data show that, in contrast to hexon
CTLs, central memory type DNA polymerase CTLs dominate the lymphoid compartment and kill fibroblasts earlier after
infection without requiring exogenous IFN-c. Thus, use of CTLs targeted to both early and late Ad proteins may improve the
efficacy of immunotherapy for life-threatening Ad disease in SCT recipients.
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Introduction
Adenoviruses (Ads) may cause invasive, life-threatening infec-
tions in hematopoietic stem cell transplant (SCT) recipients,
especially in the pediatric population, such as hepatitis, pneumo-
nitis, colitis, nephritis, and encephalitis [1,2]. The profound
immune suppression following allogeneic bone marrow transplan-
tation, due to ablation of host T cell immunity and administration
of immunosuppressive drugs to prevent or treat graft vs. host
disease makes patients susceptible to both reactivation of latent Ad
infections and primary Ad infections [3]. Group C serotypes (Ad
types 1, 2, and 5) common in the general population and the
uncommon group B serotypes (Ad types 11 and 35) have most
frequently been associated with disease post-SCT, but infections
with most serotypes have been described [4,5]. Although
treatment with the toxic antiviral cidofovir may inhibit Ad
replication, patients need to develop cell-mediated immunity to
recover from invasive Ad disease [6–8].
Given the limited therapeutic options, donor lymphocyte
infusions have been under investigation as a treatment for Ad
disease in allogeneic SCT recipients. As a precedent, infusions of
donor lymphocytes or virus-specific T cells have been effective in
the treatment of Epstein Barr virus-associated lymphoproliferative
disease and cytomegalovirus infections in SCT recipients [9,10].
Case reports of donor lymphocyte infusions have suggested some
benefit against invasive Ad disease [11–13]. More recently, Ad-
specific T cells, isolated by collecting IFN-c-secreting T cells after
short in vitro stimulation with Ad lysate, were infused into 8
pediatric SCT pediatric recipients with Ad infections [14]. Patients
were also treated with cidofovir. Four of 5 patients with diarrhea
alone or no symptoms resolved their infections, whereas all 3
patients with disseminated Ad disease died. In another study, 11
SCT recipients were treated with donor lymphocytes stimulated in
vitro with autologous lymphoblastoid cell lines infected with an E1-
deleted Ad [15]. Ad-specific T cell responses were detected only in
patients (5) with positive Ad cultures. Reductions in Ad viral loads
were documented in 3 pediatric patients, and clinical improve-
ment noted in one patient with Ad pneumonia.
A detailed understanding of the T cell response to Ad is
required to identify antigen-specific donor T cells that have rapid
responses, high proliferation potential, and longevity in order to
optimize immunotherapy strategies. Recent advances in T cell
biology have shown that two main cell types are involved in
memory CD8+ T cell responses – effector memory cells (Tem)
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CCR7+) [16,17]. Tcm are concentrated in secondary lymphoid
tissue and have limited effector functions, but they are highly
efficient in self renewal and divide in response to homeostatic
cytokines including IL-7 and IL-15. Tem, on the other hand,
migrate to peripheral tissues and exhibit pronounced immediate
cytolytic (effector) activity but only modest proliferation upon
antigenic stimulation. Together, Tem and Tcm contribute to
protective immunity depending on the nature and route of
infection. Additional levels of complexity in memory CD8+ T cell
phenotypes exist between distinct peripheral tissues and in
different infectious models [18]. Such functional, anatomic, and
phenotypic heterogeneity in the CD8+ T cell memory pool has
significant consequences for immunotherapy strategies. Therefore,
it is important to determine both the T cell subset(s) and the viral
antigen targets able to generate the most efficacious recall
responses to Ads.
Additionally, itis crucial to take into consideration the fact that Ads
express unique immune evasion proteins that help the virus evade T
cell recognition. Notably, the Ad early region 3 E3-19K glycoprotein
specifically downregulates cell surface expression of MHC class I
molecules, which inhibits recognition of infected cells by CD8+ T
cells [19] E3-19K binds to both classImolecules and TAPproteins in
the endoplasmic reticulum, which efficiently prevents class I antigen
transport to the cell surface [20]. Thus, elimination of infected cells
prior to E3-19K mediated downregulation of MHC class I molecules
may be more efficient in controlling Ad replication and dissemina-
tion. Targeting cells early after infection may also help avoid the
effects of other early Ad proteins such as the E3-10.4K/14.5K RID
complex (receptor internalization and degradation) and E3-14.7K
that confer resistance to apoptosis [21].
We have previously shown that both early regulatory proteins
and late structural proteins from Ad can be recognized by human
CD8+ CTLs [22,23]. Additionally, our lab has identified several
HLA-A2 restricted epitopes from the early region 2 protein DNA
polymerase (e.g P-977) and late capsid protein hexon (e.g. H-892)
that are well conserved among different Ad serotypes. Hexon
represents the most abundant viral protein and is synthesized late
after infection following DNA replication. Rooney and colleagues
have also identified other CD8+ T cell epitopes from hexon [24].
Most groups arenow focused on expanding hexon-specific T cells ex
vivo for immunotherapy of Ad disease in SCT recipients [25–27].
The goal of this study was to compare the frequency, memory
and activation phenotypes, and functional aspects of early protein
DNA polymerase- and late protein hexon-specific CD8+ T cells in
both peripheral blood and tonsils directly ex vivo. CD8+ T cells
targeted to HLA-A2 restricted epitopes P-977 from the DNA
polymerase and H-892 from hexon were measured ex vivo using
epitope-specific pentamers. Activation and lymphocyte homing
markers and cytokine expression were compared between early
and late protein-specific CD8+ T cells in both PB and tonsils.
Additionally, P-977 and H-892 epitope specific CTL lines were
generated from PBMC by in vitro stimulation with Ad5-infected
dendritic cells (DC), followed by stimulation with peptide, to
compare the kinetics of cytotoxicity.
Methods
Study participants
Buffy coat collections were obtained from healthy adult
volunteers through the Thomas Jefferson University Hospital
Blood Donor Center. Additionally, 1–2 blood specimens (50 ml
each) were obtained from SCT recipients with documented
invasive Ad infections. Tonsil samples were obtained from patients
undergoing tonsillectomies at Thomas Jefferson University
Hospital. The research protocols were approved by the Institu-
tional Review Board. All donors were screened by HLA typing or
flow cytometry with HLA A2-specific antibody W6/32 to identify
HLA A2-positive donors.
Purification of lymphocytes
Lymphocytes were purified from PBMC by density gradient
centrifugation using Ficoll-Hypaque (Sigma Aldrich, St. Louis,
MO). For purification of lymphocytes from tonsils, tonsil tissue was
cut into small fragments and cells were dispersed by vigorously
agitatingsamplewiththeflatendofa 5 mlsyringeagainst bottom of
culture dish on ice. The fractionated tonsil specimen and cellular
suspensionwerepassedthrougha 100 mm sieveandrinsedwellwith
cold HBSS, until the tissue was clear. Cells were resuspended by
repeated pipetting until all cell clumps dissolved and then under-
layed with Ficoll-Hypaque. The cell suspension was spun at 9006g
for 30 min without brakes, and mononuclear cells at the interphase
were harvested. Lymphocytes were aliquoted in media containing
10% DMSO and stored in liquid nitrogen until use.
Viruses
Group C Ad5 prototype strain was originally obtained from M.
Horowitz, Albert Einstein College of Medicine (Bronx, NY). The
Ad5 E3-19K deletion mutant dl704 was obtained from W. Wold,
St. Louis University (St. Louis, MO) [28]. Ad virions were purified
from virus-infected A549 cell lysates by an affinity chromatogra-
phy method (Clonetech, Mountain View, CA) as per the
manufacturer’s instructions. The Ad5 virion preparation was
titered by ELISA (Cell Biolabs, San Diego, CA).
Synthetic peptides
The HLA-A2-restricted epitopes H-892 (LLYANSAHAL) and
P-977 (VLAWTRAFV) were previously identified from the Ad5
hexon and DNA polymerase protein sequences, respectively.
Crude peptides were synthesized by Research Genetics (Hunts-
ville, AL) or Sigma-Genosys (The Woodlands, Texas). Stock
solution (10 mM) for each peptide was prepared in 90% DMSO
and stored in small aliquots at 280uC.
IFN-c ELISPOT assay
This assay was performed as previously described [29].
Pentamer staining and flow cytometry assays (CFC)
APC-labeled MHC class I HLA A2 Pro5
Tm Pentamers with H-
892 and P-977 peptides were custom synthesized at ProImmune
(Oxford, UK). PE-labeled mAbs to human CCR7, CD25, TNF-a,
IL-2, Perforin, INF-c and FITC-labeled human anti-CD8 were
purchased from BD Pharmingen (San Diego, CA). For immuno-
staining, 1–2610
6 lymphocytes were stained with a pre-titered
amount of pentamer reagent (HLA A2:H-892 or HLA A2:P-977)
at room temperature, shielded from light, for 20 min. HLA A2
negative control Pro5
Tm Pentamers were included to assess
nonspecific binding in flow assays. Cells were washed and then
stained with PE-labeled CD8, CD25, or CCR7 mAbs on ice for
20 min. Thereafter cells were washed and fixed in 0.4%
formaldehyde solution. Cell surface phenotype analysis was done
by gating on the CD8+ pentamer+ population.
Cytokine analysis
CD8+ T cells were isolated from PBMC or tonsils by negative
immunomagnetic selection (Miltenyi Biotec, Auburn, CA), and
analyzed by intracellular cytokine staining and flow cytometry.
Adenovirus Specific CTLs in PBMCs and Tonsils
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6 CD8+ T lymphocytes were incubated with or
without peptide for 2 h. Cells were treated with brefeldin A (Golgi
Stop, BD Pharmingen) for an additional 4 h and then washed,
permeabilized, and fixed using the Cytofix/Cytoperm reagent (BD
Pharmingen). PE-conjugated anti-human IFN-c, TNF-a, perforin
and IL-2 mAbs were used to measure cytokine secretion. PE-
conjugated isotype control cocktail as well as purified blocking
antibody cocktail were used to measure background. Samples were
collected on a FACSCalibur flow cytometer (BD Pharmingen),
and analysis was performed using CellQuest software.
Statistical analysis
Differences in values between experimental groups were
examined for significance with Graph Pad Prism software using
the Student t test. A probability (P) values ,0.05 was considered
significant.
Reverse transcriptase PCR (RT PCR)
The kinetics of mRNA expression from the Ad DNA
polymerase and hexon ORFs was measured by infecting
fibroblasts with wild type (WT) Ad5 (200 pfu/cell) and harvesting
cells between 6–24 h post infection. RNA was extracted from
infected cells via affinity chromatography (Qiagen, Valencia, CA)
and RT PCR was performed using the Quantiscript
TM RT
(Qiagen). The following primers were used for amplification of
DNA polymerase - (forward): 59 GACTTCACTCTAGAAA-
GATGATACTCAGAGAGCCCCTC 39 and (reverse): 59
GACTTCACGGATCCTAACTGGAGGAGGCGCCGCA 39 -
and hexon - (forward): 59 GACTTCACTCTAGAAGGTCAG-
GAAAATGGATGGG 39 and (reverse): 59 GACTTCACTCTA-
GAGATTCCCCAGTCCTTTTCCTCCC 39 - to produce 1 Kb
and 0.3 Kb products, respectively. A control reaction without RT
was run for each time point to ensure that the RT PCR products
were RNA specific.
Preparation of Ad-infected dendritic cells
CD14+ cells were isolated from PBMC by positive immuno-
magnetic selection (Miltenyi Biotec) per the manufacturer’s
directions. CD14+ cells (1610
6/ml) were placed in a 6-well plate
in RPMI 1640 supplemented with 5% human AB sera, HEPES,
glutamine, and P/S containing GM-CSF (800 U/ml) (Berlex,
Wayne, NJ) and IL-4 (1000 U/ml) (BD Pharmingen). Fresh
cytokines were added on day 3. Non-adherent cells (immature DC)
were harvested on day 5 and infected with Ad (200 pfu/cell) in
200 ml media for 1.5 h or left untreated. DC were re-plated in 6-
well plates, and maturation was induced by incubation with
10 ng/ml IL-1b, 1000 U/ml IL-6, 10 ng/ml tumor necrosis
factor-a (TNF-a) (BD Pharmingen), and 1 mg/ml prostaglandin
E2 (PGE2) (Sigma Aldrich) for 48 h.
Generation of peptide-specific CTL lines
Bulk Ad-specific T cells were amplified in vitro by co-culture of
10610
6 lymphocytes with 2610
6 Ad5-infected DCs for one week.
Then, cells were re-stimulated with peptide (H892 or P977)-
loaded, irradiated PBMC on day 7. IL-2 (20 U/ml) was added to
each line on day 8, and every 3 to 4 days thereafter. Specificity was
confirmed by IFN-c ELISPOT and the CTL lines were assayed
for cytotoxicity around day 14.
Cytotoxic T cell assay
Cytotoxicity was measured by a calcein release assay as
previously described [29]. HLA-A2-positive MRC-5 fibroblasts
(targets) were infected for 6, 8, 12, 16 or 24 h with Ad5 (200 pfu/
cell). In some cases, fibroblast targets were pre-treated for 24 h
with 150 U/ml of human IFN-c prior to infection. Targets were
labeled with 5 mg/ml calcein (Molecular Probes, Eugene, OR) for
30 min at 37uC, washed extensively, and incubated with effectors
in microtiter wells for 3 h. Assays were performed in triplicate
using a range of effector/target ratios. Calcein release was
measured from supernatants on a Victor 2 1420 multilabel
counter (Wallace, Gaithersburg, MD).
Proliferation assay
Proliferation of lymphocytes in vitro was measured using CFSE
(Molecular Probes) labeling. Briefly, 20610
6 purified CD8+ T cells
were labeled with 1.5 mM CFSE in PBS for about 8 min. Cells
were then incubated for 10 min at 37uC with pre-warmed FBS to
allow for efflux of excess CFSE. Cells were washed vigorously
three times in PBS containing 1% FBS, and a day 0 sample was
obtained to determine initial labeling. For peptide stimulation
experiments, 2610
6 CFSE-labeled cells were placed in a 24-well
plate and cultured in RPMI with 10% FBS with or without P-977
or H-892 peptides for 4 days.
Results
Early and late protein-specific CTLs can be detected in
peripheral blood and lymphoid tissue
Nine HLA A2-positive donors were tested for CD8+ T cell
responses to both early and late protein HLA A2-restricted
epitopes P-977 and H-892 in PB by ex vivo pentamer staining.
These epitopes are both highly conserved among different Ad
serotypes. PBMC samples were obtained from three different
groups of individuals: 1) six healthy adults; 2) one recently infected
immunocompetent adult; and 3) two adult SCT recipients who
recently recovered from documented invasive Ad infections (2 and
12 months post-infection). All donors had positive T cell responses
to Ad lysate by IFN-c ELISPOT assay (data not shown). Overall,
as shown in Figure 1A, P-977+CD8+ T cells were detected at
lower frequencies than H-892+CD8+ T cells in PB (mean 0.38%
vs 0.57%, p=0.03). Recently infected donors (immunocompro-
mised and immunocompetent) exhibited high, comparable
frequencies of P-977- and H-892-specific CD8+ T cells
(Figures 1A, 2A). In contrast, the frequencies of P-977+CD8+
T cells were relatively lower than H-892+CD8+ T cells in PB
samples from healthy adults. Two of 6 healthy donors did not have
detectable H-892 or P-977 responses in PB, while one donor had a
low H-892 response but no P-977 response using this method.
Tonsils from 5 of 5 HLA A2+ donors tested exhibited positive
responses to one or both epitopes by ex vivo pentamer staining
(Figures 1B, 2B). Notably, in contrast to PB responses, P-
977+CD8+ T cells were detected at significantly higher frequencies
thanH892+CD8+T cellsintonsils(mean1.1%vs.0.48%,p=0.01).
One tonsil sample exhibited a high frequency of P-977+CD8+ T
cells (1.1%) but did not have a detectable H-892 response.
Early and late CTLs from peripheral blood and tonsils
have distinct phenotypes
Cell surface expression of the lymph node homing receptor
CCR7 and the activation receptor CD25 (IL-2R) was analyzed in
PB and tonsil mononuclear cell samples. CD8+ T cells from both
early protein P-977 pentamer+ and late protein H-892 pentamer+
populations had negligible cell surface expression of CCR7 in all
PB samples (Figure 3A). In contrast, CCR7 was highly expressed
in tonsil samples by both early and late protein pentamer+ CD8+
T cells. The signature of the T cell activation receptor CD25 was
more diversified. PB samples from remotely infected adults showed
Adenovirus Specific CTLs in PBMCs and Tonsils
PLoS ONE | www.plosone.org 3 May 2011 | Volume 6 | Issue 5 | e20068Figure 1. CD8+ T cell responses to DNA polymerase (P-977) and Hexon (H-892) epitopes in peripheral blood and tonsils.
Lymphocytes from peripheral blood (PB) or tonsil samples were stained with anti-CD8-FITC mAb and either early protein P-977 or late protein H-892
APC-labeled HLA A2 pentamers and analyzed by flow cytometry. Comparison of the frequencies of P-977+ CD8+ T cells and Hex-892+ CD8+ T cells in
all donor samples from PB (A) and lymphoid compartments (B). Remotely infected adult (#). Recently infected immmunocompromised adult (&).
Recently infected immunocompetent adult (N).
doi:10.1371/journal.pone.0020068.g001
Figure 2. Representative DNA polymerase (P-977) and Hexon (H-892) pentamer staining patterns in peripheral blood and tonsil.
Lymphocytes from peripheral blood (PB) or tonsil samples were stained with anti-CD8-FITC mAb and either P-977 or H-892 APC-labeled HLA A2
pentamers and analyzed by flow cytometry. Cells were also stained with HLA A2 negative control pentamers. A. PB from a recently infected
immunocompetent adult (i), recently infected immunocompromised adult (ii), and remotely infected adult (iii). B. Tonsil sample.
doi:10.1371/journal.pone.0020068.g002
Adenovirus Specific CTLs in PBMCs and Tonsils
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populations (Figure 3B). P-977+CD8+ T cells from remotely
infected adult PB showed low expression of CD25, whereas most
H-892+CD8+ T cells were positive for CD25. In comparison, the
vast majority of both early and late protein epitope+ CD8+ T cells
from recently infected donor PB (both immunocompetent and
immunocompromised) exhibited cell surface expression of CD25.
Tonsil samples had negligible expression of CD25 from both early
and late protein epitope-specific CD8+ T cells consistent with a
central memory phenotype, except for 1 tonsil that exhibited
moderate expression of CD25 from P-977+CD8+ T cells only.
Functional profile of peripheral blood and tonsil P-977-
and H-892-specific CD8+ T cells
Cytokine secretion and proliferative potential of early and late
protein epitope-specific CD8+ T cells from lymphoid tissue and
PB were compared. Within each compartment, early P-977- and
late H-892-specific CD8+ T cells had similar cytokine secretion
profiles by intracellular cytokine flow analysis. IFN-c, TNF-a, and
perforin were expressed by PB CD8+ T cells stimulated 6 h with
either the P-977 or H-892 peptide, but there was relatively little
IL-2 secretion (Figure 4, Figures S1, S2, S3). The cytokine
release pattern in tonsils was distinct from that of PB samples.
Lymphoid CD8+ T cells had significant release of both IL-2
(which was negligible in PB CTLs) and IFN-c but expressed little
or no perforin and TNF-a when stimulated in vitro with either
peptide).
The proliferative potential of lymphoid and PB epitope-specific
CD8+ T cells was also compared by CFSE staining following in
vitro antigen exposure for 4 days from single donors (Figure 5).
Lymphoid CD8+ T cells exhibited a higher proliferative potential
than PB CD8+ T cells when stimulated with either P-977 or H-
892 peptides. Additionally, within both compartments, early P-
977-specific CD8+ T cells had a higher proliferative potential than
late H-892 peptide-specific T cells. Thus, early protein P-977
CD8+ T cells from the lymphoid compartment had the highest
proliferation potential of all.
P-977-specific and H-892-specific CTLs have distinct
cytotoxicity profiles
PB lymphocytes from one of the healthy donors were stimulated
in vitro with Ad-infected DCs for 1 week, followed by stimulation
with individual peptides, to generate early protein P-977 and late
protein H-892 peptide-specific CTLs (as described in methods).
These early P-977 or late H -892 CTLs were incubated with
fibroblast targets infected with either WT Ad5 or the Ad5 E3-19K
deletion mutant dl704. Targets were infected for 6, 8, 12, 16, or
24 h, and cytotoxicity was measured by calcein release assay (as
described). Early P-977 CTLs lysed WT Ad5-infected targets as
soon as 8 h post infection (Figure 6A(i)); cytotoxicity peaked at
12 h and was absent at later time points. In the absence of E3-19K
expression, early P-977 CTLs were able to lyse Ad dl704-infected
cells efficiently up to 16 h post infection (Figure S4). In contrast,
late H-892 CTLs did not efficiently kill WT Ad5-infected targets
(Figure 6B(i)). Our lab has previously shown that IFN-c can help
overcome the E3-19K-mediated inhibition of class I cell surface
expression [30]. Therefore, fibroblast targets were treated with
IFN-c prior to infection, and the cytotoxicity assays were repeated.
As shown in Figure 6A(ii), the early P-977 CTLs lysed WT Ad5-
infected targets pre-treated with IFN-c 8 h post infection, and
cytotoxicity peaked at 16 h, similar to the kinetics using dl704-
infected fibroblasts. Moreover, as shown in Figure 6B(ii), late H-
892 CTLs efficiently killed WT Ad5-infected targets pre-treated
with IFN-c, but cytotoxicity did not occur until 16–24 h post
Figure 3. Expression of homing and activation markers in epitope-specific CD8+ T cells from peripheral blood and tonsils. Early P-
977 pentamer+ and late H-892 pentamer+ CD8+ T cells from peripheral blood (PB) or lymphoid tissue (LT) samples were stained with either T cell
activation marker CD25 or lymph node homing receptor CCR7 PE-labeled mAbs. A. Comparison of the proportion of P-977+CD8+ T cells and H-
892+CD8+ T cells expressing CCR7 in PB and.LT samples. B. Comparison of the proportion of P-977+CD8+ T cells and H-892+ CD8+ T cells expressing
CD25 in PB and LT samples. Recently infected immunocompromised adult (&). Recently infected immunocompetent adult (N). Remotely infected
healthy donor (#).
doi:10.1371/journal.pone.0020068.g003
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infected fibroblasts without IFN-c pre-treatment at 16–24 h
(Figure S4). These data confirm the role of E3-19K in inhibiting
CTL recognition of hexon but not DNA polymerase.
Finally, the kinetics of DNA polymerase and hexon expression
was studied by RT-PCR analysis of Ad5-infected fibroblasts.
Robust expression of DNA polymerase mRNA was observed as
early as 8 h post infection and started to decline by 16 h
(Figure 6C). In contrast, hexon mRNA could not be detected
until 12 h following infection and expression peaked at 16–24 h
post infection. The kinetics of mRNA expression paralleled the
above cytotoxicity data in that early protein P-977 CTLs started
killing infected cells at 8 h, whereas late protein H-892 CTL
cytotoxicity was delayed until 16 h post infection.
Discussion
A detailed understanding of Ad-specific T cell responses is
needed in order to optimize immunotherapy strategies for SCT
recipients infected with Ads, pathogens which may be associated
with significant morbidity and mortality [31,32]. Although most
healthy adults exhibit memory T cell responses to Ads, little is
known about the kinetics or memory compartmentalization of Ad-
specific T cells. This is the first study to identify the phenotype and
functional status of Ad-specific CD8+ T cells in tonsils and to
compare the responses of secondary lymphoid and PB compart-
ments following natural Ad infection. Additionally, this study
compares the characteristics of CTLs targeted to highly conserved
epitopes from the early regulatory protein DNA polymerase and
late capsid protein hexon in both PB and lymphoid compartments.
This study documents that DNA polymerase-specific CTLs kill
fibroblasts earlier after infection than hexon-specific CTLs, prior
to Ad E3-19K-mediated down regulation of HLA class I
expression. Additionally, central memory type CTLs targeted to
DNA polymerase dominate the lymphoid compartment and have
a higher proliferative potential compared to hexon-specific CTLs.
CD8+ T cell responses to HLA A2-restricted epitopes from
DNA polymerase (P-977) and hexon (H-892) were detected in
Figure 4. Functional analysis of DNA polymerase and hexon epitope-specific CD8+ T cells from peripheral blood and tonsils. Purified
CD8+ T cells from peripheral blood (PB) or lymphoid tissue (LT) samples were stimulated (stim) with either P-977 or H-892 peptides for 6 h. Samples
were assayed for intracellular cytokine expression of IFN-c (A), TNF-a (B), IL-2 (C), and perforin (D). Recently infected immunocompromised adult, H-
892 (&) or P-977 (N). Remotely infected adult, Hex 892 (%) or P-977 (#).
doi:10.1371/journal.pone.0020068.g004
Adenovirus Specific CTLs in PBMCs and Tonsils
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Recently infected subjects exhibited high, comparable frequencies
of P-977+CD8+ and H-892+CD8+ T cells in PB. Although, as
expected, remotely infected donors exhibited significantly lower
responses to Ad-specific epitopes in PB, H-892+CD8+ T cells were
detected at significantly higher levels than P-977+CD8+ T cells. In
contrast, there were significantly higher frequencies of P-
977+CD8+ T cells compared to H-892+CD8+ T cells in tonsil
samples. Thus, early protein DNA polymerase-specific CD8+ T
cells dominate the lymphoid compartment, while late protein
hexon-specific CD8+ T cells are predominant in PB of remotely
infected adults.
Phenotypic analysis of Ad-specific CTLs from PB and tonsils
revealed significant differences between compartments, as well as
between epitopes. Several reports have described two subsets of
memory CD8+ T cells based upon expression of lymph node
homing receptors: CD62L+CCR7+CD8+ central memory T cells
-Tcm and CD62L-CCR7-CD8+ effector memory T cells -Tem
[17,33]. In PB, both P-977+CD8+ and H-892+CD8+ T cells from
recently infected subjects exhibited high level expression of the T
cell activation receptor CD25 and were negative for the lymphoid
homing marker CCR7. In tonsils, on the other hand, both P-
977+CD8+ and H-892+CD8+ T cells exhibited negligible
expression of CD25 and high expression of CCR7. Thus, P-977-
specific CD25-CCR7+ CD8+ Tcm-like cells predominate in the
lymphoid organs while H-892-specific CD25+CCR7-CD8+ Tem-
like cells are found mostly in PB. Interestingly, there was a mixed
phenotype of Ad-specific CD8+ T cells in PB from remotely
infected adults. Although Ad-specific T cells from PB in remotely
infected subjects were all CCR7 negative and most P-977+CD8+
T cells did not express CD25, the majority of the higher frequency
H-892+CD8+ T cells were CD25+, similar to the phenotype in
recently infected adults.
These data suggest that over time following infection, DNA
polymerase-specific CTLs preferentially home to secondary
lymphoid tissue, while hexon-specific CTLs remain in PB. This
is consistent with the fact that DNA polymerase is a regulatory
protein that is expressed transiently in active infection, as reflected
by the cytotoxicity and RT-PCR kinetics data presented, and thus
there is little if any residual antigen in vivo. In contrast, hexon is
the major capsid protein in the virion and is over-expressed in Ad-
infected cells. Therefore, hexon-specific CTLs likely remain in an
activated state in PB due to persistent antigen exposure. Studies
have documented the persistence of viral antigens from other lytic
viruses such as influenza and vesicular stomatitis virus [34,35].
More recently, respiratory DCs that migrate to draining lymph
nodes were identified as the major source of persistent antigen
following acute influenza virus infection [36]. The presence of
Figure 5. Functional analysis of DNA polymerase and hexon epitope specific CD8 T cells using proliferation assay. CFSE-labeled CD8+
T cells from tonsils (A) or PB (B) were stimulated with relevant peptides (P-977 or H-892 or media) for 4 days. Flourescence intensity of day 0 (shaded
area) and day 4 samples was compared.
doi:10.1371/journal.pone.0020068.g005
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may also reflect persistent low level Ad replication and/or boosting
of hexon-specific T cells by re-exposure to exogenous Ads.
The central memory type CTLs (Tcm) are considered the
‘‘true’’ memory subset of CD8+ T cells, and several reports have
documented that viral replication in vivo is more effectively
controlled by CD8+ Tcm [37,38]. Wherry et al also showed that
CD8+ Tcm are able to persist long term in vivo by self renewal, are
able to secrete IFN-c, and rapidly expand upon re-encounter with
pathogen [17]. CD8+ Tcm were also shown to elicit greater
protection against experimental tumors after adoptive transfer
followed by vaccination [39]. Analysis of cytokine expression and
proliferation demonstrated functional differences in Ad-specific T
cells primarily based upon the compartment, not the epitope. In
PB, most CD8+ T cells targeted to either P-977 or H-892 secreted
IFN-c, TNF-a, and perforin but not IL-2, consistent with a Tem
phenotype. These data are consistent with a recent study in which
Ad E1-deleted vector-stimulated CD8+ T cells were found to
secrete both IFN-c and perforin; however, TNF-a secretion was
not detected [40]. Tonsil T cells targeted to either P-977 or H-892
Figure 6. Kinetics of cytotoxicity of DNA polymerase (P-977) and hexon (H-892) specific CTLs. P-977- and H-892-specific CTL lines were
tested for cytotoxicity against fibroblast targets infected with wildtype Ad5 using a 3 h calcein release assay. Fibroblasts were infected with Ad5 for 8
to 24 h prior to assay; uninfected fibroblasts were used as a negative control. A. Cytotoxicity of P-977-specific CTLs against fibroblast targets without
IFN-c pretreatment (i) or pretreated with IFN-c (ii). B. Cytotoxicity of H-892-specific CTLs against fibroblast targets (i) without IFN-c pretreatment or
(ii) pretreated with IFN-c. C. Expression of DNA polymerase and hexon mRNA was measured in fibroblasts infected with WT Ad5 for 6–24 h. mRNA
was amplified by 2 step RT-PCR using primers for (i) DNA polymerase and (ii) hexon. A control reaction in which cDNA product was amplified in the
absence of reverse transcriptase (RT) was included for each time point. M, 1Kb ladder (i); PCR marker ladder (Promega, WI) (ii).
doi:10.1371/journal.pone.0020068.g006
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of perforin and TNF-a consistent with a CD8+ Tcm phenotype.
Additionally, Tcm-type tonsil CTLs showed higher proliferative
potential when stimulated with cognate antigen in vitro than Tem-
type PB derived CTLs. In both compartments, however, P-977-
specific CTLs exhibited a higher proliferative ability than H-892-
specific CTLs.
The fact that lymphoid derived Tcm and DNA polymerase-
specific CTLs have a proliferative advantage over hexon-specific
CTLs has implications for protective immunity, as more rapid
proliferation will eventually lead to greater expansion of this subset
in vivo. Additionally, only Tcm-type tonsil CTLs produced IL-2,
consistent with their greater potential for in vivo expansion. Ad-
specific Tcm may also be exposed to more efficient antigen
presentation in vivo as these CTLs home to primary and secondary
lymphoid organs. Infusion of large number of Tem-type cells may
provide immediate protection but fail to reconstitute long term
memory [41]. Thus, for immunotherapy applications, the superior
ability of Tcm to reconstitute the memory T cell pool may be
highly relevant. Based on other studies, it may also be important to
infuse both CD4+ and CD8+ Ad-specific T cells in order to help
amplify and maintain CD8+ T cell responses [9,42],
Notably, P-977 CTLs lysed fibroblasts in vitro significantly earlier
following infection compared to H-892 CTLs and evaded E3-
19K-mediated inhibition of cytotoxicity. In parallel with the
kinetics of mRNA expression, P-977 CTLs killed fibroblasts as
early as 8 h post infection. In contrast, H-892 CTLs were unable
to kill infected fibroblasts unless targets were treated with IFN-c to
up regulate HLA class I antigens prior to infection, and
cytotoxicity was delayed until 16–24 hours. This result confirms
our prior study in which bulk Ad-specific CTLs did not kill
infected fibroblast targets without IFN-c pre-treatment as a result
of E3-19K-mediated down regulation of class I antigens [30].
Thus, CTLs targeted to DNA polymerase may be able to more
rapidly and efficiently eliminate Ad-infected cells in vivo compared
to hexon-specific CTLs. Targeting Ad-infected cells prior to viral
DNA replication will also prevent new virus production.
We acknowledge that the small sample size is a major limitation
of this study. Unfortunately, acute Ad infections are infrequently
identified in adults and the number of adult SCT patients who
develop and recover from invasive Ad infections is very limited. It
took several years to identify the 3 HLA-A2 positive recently
infected donors used in this study. Additionally, we had access to a
limited number of PBMC from each donor, especially the recently
infected patients, so analyses had to be carefully selected. Although
there were statistically significant differences in the precursor
frequencies of H-892- and P-977-specific CD8+ T cells in PB and
tonsil samples, the differences in cytokine expression and
proliferation need to be confirmed in a larger study. Also, these
analyses were performed using a single epitope for each protein,
which may not necessarily reflect the total CTL response to each
protein. Additionally, the intracellular cytokine analysis was done
with a single stain at a time, so this study did not characterize the
expression of multiple cytokines from individual cells. Finally,
although it would be ideal to evaluate the protective potential of
these CTLs after adoptive transfer in an animal model, a suitable
animal model that mimics human Ad infection is not available,
and animal Ads, such as mouse Ads, have significantly different
properties [43].
In summary, these data show that in contrast to hexon-specific
CTLs, central memory type CTLs targeted to DNA polymerase
dominate the lymphoid compartment and have a higher
proliferative potential. Additionally, DNA polymerase-specific
CTLs kill fibroblasts earlier after infection compared to hexon-
specific CTLs, prior to both E3-19K-mediated down regulation of
HLA class I expression and Ad replication. In contrast, hexon
CTLs cannot recognize Ad-infected cells unless exposed to
exogenous IFN-c to maintain HLA class I expression. Thus, use
of CTLs targeted to both early protein DNA polymerase and late
protein hexon may improve the efficacy of immunotherapy for
life-threatening Ad disease in SCT recipients.
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Figure S1 Intracellular cytokine staining of purified
CD8+ T cells stimulated with H-892, P-977, or media
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Figure S2 Intracellular cytokine staining of purified
CD8+ T cells stimulated with H-892, P-977, or media
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Ad5 E3-19K deletion mutant dl704.
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